Dr. Poorana Ganga Devi N
Dr. Poorana Ganga Devi N
Designation: Scientist D
Division/Unit: Clinical Research
Email: poornaganga[dot]devi[at]icmr[dot]gov[dot]in
Educational Qualification
MBBS, PGDPH, MPH
Personal Statement
As a clinical research scientist in tuberculosis (TB), I am committed to advancing evidence that improves patient care and outcomes. My work focuses on evaluating treatment responses, drug resistance, and post-TB lung impairment through well-designed clinical studies. At ICMMR-NIRT, I collaborate with multidisciplinary teams to translate research findings into practical interventions for TB control. With expertise in clinical trial coordination, data analysis, and patient-centered research, I strive to bridge science and healthcare delivery.
Research Focus
• Clinical and translational research in tuberculosis, focusing on treatment outcomes and post-TB sequelae.
• Evaluation of rehabilitation and preventive strategies to improve respiratory outcomes in TB survivors.
• Integration of pulmonary function assessment into clinical research and public health programs for comprehensive TB care.
• Clinical trial design and implementation, with emphasis on therapeutic interventions.
• Epidemiological and operational research aimed at strengthening TB control and healthcare delivery systems.
Ongoing projects as Principal investigator
Effect of Pulmonary rehabilitation on the exercise tolerance in sputum positive pulmonary TB patients.
Significant Publications
• Navaneethapandian Pooranagangadevi, Chandrasekaran Padmapriya, Review article on “Treatment of Tuberculosis and the drug interactions associated with HIV-TB co-infection treatment”, Front. Trop. Dis., 13 May 2022, https://doi.org/10.3389/fid.2022.834013
• Padmapriyadarsini C, Mamulwar M, Mohan A, et al., Randomized trial of Metformin with Anti-tuberculosis Drugs For Early Sputum Conversion in Adults with Pulmonary Tuberculosis, Clin Infect Dis. 2021 Nov 26; doi:10.1093/cid/ciab964
• Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, et al., Sputum culture conversion with moxifloxacin-containing regimens in newly diagnosed sputum-positive pulmonary TB in South India, Clin Infect Dis. 2014 Nov;59(10):e142-9. doi:10.1093/cid/cit550
